Botswana-Baylor Children's Clinical Centre of Excellence: The role of a paediatric centre of excellence in assuring the prioritisation and quality of paediatric care within a developing national HIV care programme

Southern African Journal of HIV Medicine

Volumn , Issue 19, 2005, Pages 42-46

  Lowenthal, Elizabeth D ^a   Anabwani, Gabriel M ^a   Jibril, Haruna B ^b   Barr, Beth ^a   Rankopo, Opelo M ^a   Kline, Mark W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b PRINCESS MARINA HOSPITAL   (Botswana)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BOTSWANA; CHILD; CHILD HEALTH CARE; EPIDEMIC; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH EDUCATION; HEALTH PRACTITIONER; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL SERVICE; MORTALITY; PATIENT CARE; PEDIATRIC HOSPITAL; SOCIAL PSYCHOLOGY; SUPPORT GROUP; TREATMENT OUTCOME;

EID: 21044442389     PISSN: 16089693     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. UNAIDS. 2004 Report on the global AIDS epidemic. http://www.unaids.org/wad2004/report.html (accessed 2 April 2004).
2. Newell ML, Coovadia H, Cortina-Borjam, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364: 1236-1243.
3. McConnell MS, Byers RH, Frederick T, et al. Trends in antiretroviral use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001. JAIDS 2005; 389(4): 488-494.
4. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001; 345: 1522-1528.
5. de Martino M, Tovo P, Balducci P, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 2000; 284: 190-197.
6. Kline MW, Matusa RF, Copaciu L, et al. Comprehensive pediatric human immunodeficiency virus care and treatment in Constanta, Romania. Implementation of a program of highly active antiretroviral therapy in a resource-poor setting. Pediatr Infect Dis J 2004; 23: 695-700.
7. Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, Groot R. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics 2002; 109: e25.
8. Wilfert CM, Kline MW, Futterman D, et al. Education of children with human immunodeficiency virus infection. Pediatrics 2000; 105: 1358-1360.
9. Kline MW. No greater gift than hope. Seminars in Pediatric Infectious Diseases 2003; 14: 309-313.
10. UNICEF. Reaching out to children in the WHO '3 by 5′ initiative: paediatric HIV care and treatment summary report.
11. UNICEF/WHO Technical Consultation. Improving access to appropriate paediatric ARV formulations. 3 - 4 November 2004. http://www.who.int/3by5/en/finalreport.pdf (accessed 2 April 2005).
12. United Nations Children's Fund. The State of the World's Children 2005. UNICEF, 2004.
13. Botswana National AIDS Coordinating Agency. 2003 Second Generation HIV/AIDS Surveillance Technical Report. Gaborone: Botswana National AIDS Coordinating Agency, 2003.
14. Ramiah I, Reich MR. Public-private partnerships and antiretroviral drugs for HIV/AIDS: Lessons from Botswana. Health Affairs 2005; 24: 545-551.
15. Baylor International Pediatric AIDS Initiative. HIV Curriculum for the Health Professional. Houston: Baylor College of Medicine, 2003.
16. World Health Organization. HIV medicines. 3 by 5 strategy: improving access to paediatric HIV medicines. WHO Drug Information 2004; 18: 288